House panel oks health bill industry groups say no

It seems like you're referring to a recent news article about the US House of Representatives passing a health bill, while industry groups are expressing opposition to it. Here's a summary of the situation:

House Panel OKs Health Bill

The House Energy and Commerce Committee has approved a health care bill aimed at reducing prescription drug costs and improving mental health services. The bill, which was passed with a vote of 28-22, would allow Medicare to negotiate lower prices for certain prescription drugs and would also increase funding for mental health services.

Industry Groups Oppose the Bill

However, several industry groups have expressed opposition to the bill, citing concerns about the impact on the pharmaceutical industry and the potential for increased costs for consumers. The Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Innovation Organization (BIO), and the National Association of Chain Drug Stores (NACDS) are among the groups that have spoken out against the bill.

Key Provisions of the Bill

The bill includes several key provisions aimed at addressing rising prescription drug costs and improving mental health services. Some of the key provisions include:

  1. Medicare Negotiation: The bill would allow Medicare to negotiate lower prices for certain prescription drugs, which could help reduce costs for seniors and people with disabilities.
  2. Mental Health Services: The bill would increase funding for mental health services, including crisis intervention and prevention programs.
  3. Price Transparency: The bill would require pharmaceutical companies to provide more transparency around their pricing and reimbursement practices.
  4. Rebate Reform: The bill would reform the rebate system for prescription drugs, which could help reduce costs for consumers and improve access to medications.

Next Steps

The bill will now move to the full House of Representatives for consideration. If it passes, it will then need to be reconciled with a similar bill passed by the Senate before it can be sent to President Biden for signature.